We are initiating coverage of Clinical Laserthermia Systems. With approvals already secured both in Europe and the US for its laser treatment of tumors, CLS offers significant long-term potential - particularly as recurring disposables will be its main source of sales. We view a 5% or higher market share in its cancer indications as achievable within 10 years, by when revenues should be up to SEK 1bn.